Patents by Inventor David Anstrom

David Anstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11858962
    Abstract: The present invention relates to recombinantly constructed proteins useful for analytical assays, in particular for determining in a biological sample obtained from an individual the presence of antibodies specific for a rhabdovirus. More particular, the present invention relates to a polypeptide comprising an ectodomain of a rhabdovirus glycoprotein and a heterologous multimerization domain linked to said ectodomain. In one example, a fusion protein of the formula x-y-z is provided, wherein x consists of or comprises such an ectodomain being optionally free of a furin cleavage site, y is a linker moiety, and z is a heterologous multimerization domain optionally selected from the group consisting of immunoglobulin sequence, coiled coil sequence, streptavidin sequence, fibritin sequence, and avidin sequence.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: January 2, 2024
    Inventors: David Anstrom, Eric Martin Vaughn, Arun V. Iyer, Michael B. Roof
  • Publication number: 20220160864
    Abstract: The present invention relates to recombinantly constructed polypeptides useful for preparing vaccines, in particular for reducing one or more clinical signs caused by an infection with at least one pathogen, such as clinical signs caused by a viral infection. More particular, the present invention is directed to a polypeptide comprising a Circoviridae capsid protein linked to a heterologous protein or fragment thereof, and to chimeric virus-like particles composed of such polypeptides. In one example, a fusion protein is provided which comprises PCV2 ORF2 protein linked to an immunogenic fragment of rotavirus VP8 protein, and which is usable for reducing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in swine.
    Type: Application
    Filed: October 4, 2021
    Publication date: May 26, 2022
    Inventors: David ANSTROM, Abby Rae PATTERSON, Gregory Brian HAIWICK, Wesley Scott JOHNSON, Bryon NICHOLSON, Eric Martin VAUGHN
  • Publication number: 20220160866
    Abstract: The present invention relates to recombinantly constructed polypeptides useful for preparing vaccines, in particular for reducing one or more clinical signs caused by a rotavirus infection. More particular, the present invention is directed to a fusion protein comprising in N- to C-terminal direction (i) an immunogenic fragment of a rotavirus VP8 protein and (ii) an immunoglobulin Fc fragment such as, for example, an IgG Fc fragment, wherein said fusion protein is usable in a method of reducing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in swine.
    Type: Application
    Filed: October 4, 2021
    Publication date: May 26, 2022
    Inventors: David ANSTROM, Abby Rae PATTERSON, Gregory Brian HAIWICK, Wesley Scott JOHNSON, Bryon NICHOLSON, Eric Martin VAUGHN
  • Publication number: 20210246171
    Abstract: The present invention relates to recombinantly constructed proteins useful for analytical assays, in particular for determining in a biological sample obtained from an individual the presence of antibodies specific for a rhabdovirus. More particular, the present invention relates to a polypeptide comprising an ectodomain of a rhabdovirus glycoprotein and a heterologous multimerization domain linked to said ectodomain. In one example, a fusion protein of the formula x-y-z is provided, wherein x consists of or comprises such an ectodomain being optionally free of a furin cleavage site, y is a linker moiety, and z is a heterologous multimerization domain optionally selected from the group consisting of immunoglobulin sequence, coiled coil sequence, streptavidin sequence, fibritin sequence, and avidin sequence.
    Type: Application
    Filed: February 5, 2021
    Publication date: August 12, 2021
    Inventors: David ANSTROM, Eric Martin VAUGHN, Arun V. IYER, Michael B. ROOF
  • Patent number: 9296797
    Abstract: Genetically-engineered fluorophore molecules with increased fluorescence are provided. These fluorophores are derived from the domains of phytochromes, and in particular bacterial phytochromes. Methods for generating these fluorophores and various applications of these fluorophores are also provided.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: March 29, 2016
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Andrew T. Ulijasz, Junrui Zhang, Katrina T. Forest, David Anstrom, Jeremiah R. Wagner, Richard D. Vierstra
  • Publication number: 20090061444
    Abstract: Genetically-engineered fluorophore molecules with increased fluorescence are provided. These fluorophores are derived from the domains of phytochromes, and in particular bacterial phytochromes. Methods for generating these fluorophores and various applications of these fluorophores are also provided.
    Type: Application
    Filed: July 2, 2008
    Publication date: March 5, 2009
    Inventors: Andrew T. Ulijasz, Junrui Zhang, Katrina T. Forest, David Anstrom, Jeremiah R. Wagner, Richard D. Vierstra